Corrigendum

This article refers to:

Elevated visfatin levels in overweight and obese children and adolescents with metabolic syndrome

Elevated visfatin levels in overweight and obese children and adolescents with metabolic syndrome.

Kolsgaard ML, Wangensteen T, Brunborg C, Joner G, Holven KB, Halvorsen B, Aukrust P, Tonstad S.

Scand J Clin Lab Invest. 2009;69(8):858–64.

It has come to our attention that the laboratory we use changed the analysis method for insulin during our data collection period. Before March 2007 the method used was competitive radioimmunoassay (Linco Research Inc, St Charles, MO, USA) and after March 2007 insulin levels were analyzed with noncompetitive immunofluorometric assay (DELFIA kit form Wallac OY, Turku, Finland).

We have therefore recalculated the insulin values analyzed after March 2007, and repeated the statistical analyses in table IV. The association between leptin and both insulin and HOMA became somewhat stronger, but the association between the other two adipokines and insulin or HOMA did not change.

Please find the corrected table below. The values that changed are shown in bold.

Table IV. Association between visfatin, adiponectin, leptin and insulin and insulin resistance (homoeostasis model assessment score (HOMA)), n = 173.

	Visfatin (ng/mL)		Adiponectin (ng/mL)		Leptin (pg/mL)
	β (95% CI)	pa	β (95% CI)	pa	β (95% CI)	pa
Insulin (mmol/L)	0.04 (20.17 , 0.25)	0.71	20.26 (20.37 , 20.14)	< 0.001	0.26 (0.10 , 0.42)	0.001
HOMA	0.03 (20.17 , 0.23)	0.78	20.24 (20.35 , 20.14)	< 0.001	0.26 (0.11 , 0.41)	0.001

p_a: Linear regression. Non-normally distributed variables are log-transformed.

Results from linear regression analysis are given in logarithmic values. Adjusted for age and gender.